EPC2407

Known as: Microtubule Inhibitor EPC2407 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
01220072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Tubulin-targeting compounds have a broad anticancer spectrum and are an important class of chemotherapeutic agents. Due to the… (More)
Is this relevant?
2016
2016
The goal of the present study was to examine the safety and efficacy of the vascular disrupting agent (VDA) EPC2407 (Crolibulin… (More)
Is this relevant?
2015
2015
The high mortality rate associated with castration-resistant prostate cancer (CRPC) underscores the need for improving… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2015
Review
2015
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied… (More)
Is this relevant?
Review
2013
Review
2013
Cancer is a major devastating disease, and is a leading cause of death worldwide. Despite the progress in cancer treatment… (More)
Is this relevant?
2009
2009
3569 Background: EPC2407 is a 4-aryl-chromene single isomer microtubulin inhibitor with vascular disrupting and apoptotic… (More)
Is this relevant?
Review
2009
Review
2009
Many cancer cells are known to have defects in the apoptosis machinery. Therefore identification of compounds that can activate… (More)
Is this relevant?
Review
2007
Review
2007
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… (More)
Is this relevant?